Mutant p53.associated myosin-X upregulation promotes breast cancer invasion and metastasis

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 1069-1082

  Arjonen, Antti ^a,b   Kaukonen, Riina ^a,b   Mattila, Elina ^a,b   Rouhi, Pegah ^c   Hognas, Gunilla ^a,b   Sihto, Harri ^d   Miller, Bryan W ^e   Morton, Jennifer P ^e   Bucher, Elmar ^a   Taimen, Pekka ^f   Virtakoivu, Reetta ^a,b   Cao, Yihai ^c,g,h   Sansom, Owen J ^e   Joensuu, Heikki ^d,i   Ivaska, Johanna ^a,b  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g LINKÖPING UNIVERSITY   (Sweden)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MOLECULAR MOTOR; MUTANT PROTEIN; MYO10 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL ADHESION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; DELETION MUTANT; DNA SEQUENCE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; TISSUE MICROARRAY; TUMOR INVASION; UPREGULATION; ZEBRA FISH;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SHAPE; FEMALE; GENE EXPRESSION; HUMANS; INTEGRINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION, MISSENSE; MYOSINS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN TRANSPORT; PSEUDOPODIA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; ZEBRAFISH;

EID: 84896784204     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67280     Document Type: Article

References (68)

1. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591-602.
2. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
3. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
4. Naume B, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol. 2007;1(2):160-171.
5. Faix J, Rottner K. The making of filopodia. Curr Opin Cell Biol. 2006;18(1):18-25.
6. Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9(6):446-454.
7. Arjonen A, Kaukonen R, Ivaska J. Filopodia and adhesion in cancer cell motility. Cell Adh Migr. 2011; 5(5):421-430.
8. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol. 2010;189(3):541-556.
9. Minn AJ, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518-524.
10. Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol. 2006;174(6):863-875.
11. Pelosi G, et al. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer. 2003;88(4):537-547.
12. Yoder BJ, et al. The expression of fascin, an actinbundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 2005; 11(1):186-192.
13. Kerber ML, Cheney RE. Myosin-X: a MyTH-FERM myosin at the tips of filopodia. J Cell Sci. 2011; 124(pt 22):3733-3741.
14. Berg JS, Derfler BH, Pennisi CM, Corey DP, Cheney RE. Myosin-X, a novel myosin with pleckstrin homology domains, associates with regions of dynamic actin. J Cell Sci. 2000;113(pt 19):3439-3451.
15. Zhang H, et al. Myosin-X provides a motor-based link between integrins and the cytoskeleton. Nat Cell Biol. 2004;6(6):523-531.
16. Yonezawa S, et al. Mouse myosin X: molecular architecture and tissue expression as revealed by northern blot and in situ hybridization analyses. Biochem Biophys Res Commun. 2000;271(2):526-533.
17. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2(2):a001107.
18. Caulin C, et al. An inducible mouse model for skin cancer reveals distinct roles for gain-and loss-of-function p53 mutations. J Clin Invest. 2007; 117(7):1893-1901.
19. Muller PA, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009; 139(7):1327-1341.
20. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192(2):209-218.
21. Terzian T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008;22(10):1337-1344.
22. Adorno M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137(1):87-98.
23. Roger L, Jullien L, Gire V, Roux P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci. 2010;123(pt 8):1295-1305.
24. Enerly E, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One. 2011;6(2):e16915.
25. Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550-13555.
26. Vuoriluoto K, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436-1448.
27. Voss MJ, Moller MF, Powe DG, Niggemann B, Zanker KS, Entschladen F. Luminal and basallike breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer. 2011;11:158.
28. Soule HD, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075-6086.
29. Mould AP, Akiyama SK, Humphries MJ. The inhibitory anti-beta1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function. J Biol Chem. 1996;271(34):20365-20374.
30. Mould AP, Garratt AN, Askari JA, Akiyama SK, Humphries MJ. Identification of a novel anti-integrin monoclonal antibody that recognises a ligandinduced binding site epitope on the beta 1 subunit. FEBS Lett. 1995;363(1-2):118-122.
31. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248(2):307-318.
32. Lee SL, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A. 2009;106(46):19485-19490.
33. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 2006;13(4):1033-1067.
34. Epstein CB, Attiyeh EF, Hobson DA, Silver AL, Broach JR, Levine AJ. p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors. Oncogene. 1998; 16(16):2115-2122.
35. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci. 2000;910:121-137.
36. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172(1):5-12.
37. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res. 2011;17(14):4806-4813.
38. Loi S, et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst. 2013; 105(13):960-967.
39. Guo F, Zheng Y. Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene. 2004;23(33):5577-5585.
40. Morton JP, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(1):246-251.
41. Morton JP, et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology. 2010;139(2):586-597.
42. Kennedy AL, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell. 2011;42(1):36-49.
43. Muller PA, et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 2013;32(10):1252-1265.
44. Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene. 2010;29(18):2628-2637.
45. Cermak V, Kosla J, Plachy J, Trejbalova K, Hejnar J, Dvorak M. The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells. Cell Mol Life Sci. 2010;67(20):3557-3568.
46. Sasaki AT, Chun C, Takeda K, Firtel RA. Localized Ras signaling at the leading edge regulates PI3K, cell polarity, and directional cell movement. J Cell Biol. 2004;167(3):505-518.
47. Tokuo H, Mabuchi K, Ikebe M. The motor activity of myosin-X promotes actin fiber convergence at the cell periphery to initiate filopodia formation. J Cell Biol. 2007;179(2):229-238.
48. Plantard L, Arjonen A, Lock JG, Nurani G, Ivaska J, Stromblad S. PtdIns(3,4,5)P is a regulator of myosin-X localization and filopodia formation. J Cell Sci. 2010;123(pt 20):3525-3534.
49. Svitkina TM, et al. Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell Biol. 2003;160(3):409-421.
50. Nagy S, et al. A myosin motor that selects bundled actin for motility. Proc Natl Acad Sci U S A. 2008; 105(28):9616-9620.
51. Pi X, et al. Sequential roles for myosin-X in BMP6-dependent filopodial extension, migration, and activation of BMP receptors. J Cell Biol. 2007; 179(7):1569-1582.
52. Hwang YS, Luo T, Xu Y, Sargent TD. Myosin-X is required for cranial neural crest cell migration in Xenopus laevis. Dev Dyn. 2009;238(10):2522-2529.
53. Nie S, Kee Y, Bronner-Fraser M. Myosin-X is critical for migratory ability of Xenopus cranial neural crest cells. Dev Biol. 2009;335(1):132-142.
54. Girardini JE, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011;20(1):79-91.
55. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006;6:241.
56. Rodriguez-Pinilla SM, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12(5):1533-1539.
57. Umeki N, Jung HS, Sakai T, Sato O, Ikebe R, Ikebe M. Phospholipid- dependent regulation of the motor activity of myosin X. Nat Struct Mol Biol. 2011;18(7):783-788.
58. Chinthalapudi K, et al. Mechanism and specificity of pentachloropseudilin-mediated inhibition of myosin motor activity. J Biol Chem. 2011; 286(34):29700-29708.
59. Fedorov R, et al. The mechanism of pentabromopseudilin inhibition of myosin motor activity. Nat Struct Mol Biol. 2009;16(1):80-88.
60. Bullock AN, et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A. 1997;94(26):14338-14342.
61. Beck H, Semisch M, Culmsee C, Plesnila N, Hatzopoulos AK. Egr-1 regulates expression of the glial scar component phosphacan in astrocytes after experimental stroke. Am J Pathol. 2008;173(1):77-92.
62. Arjonen A, Alanko J, Veltel S, Ivaska J. Distinct recycling of active and inactive β1 integrins. Traffic. 2012;13(4):610-625.
63. Pellinen T, Arjonen A, Vuoriluoto K, Kallio K, Fransen JA, Ivaska J. Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β1-integrins. J Cell Biol. 2006;173(5):767-780.
64. Högnäs G, et al. Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. Oncogene. 2012;31(31):3597-3606.
65. Pellinen T, Rantala JK, Arjonen A, Mpindi JP, Kallioniemi O, Ivaska J. A functional genetic screen reveals new regulators of beta1-integrin activity. J Cell Sci. 2012;125(pt 3):649-661.
66. Joensuu H, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9(3):923-930.
67. Sihto H, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008;14(13):4103-4110.
68. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-210.